Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 329

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 329
---
 time to time by the Selling Shareholder of any or all of the Ordinary Shares (represented by Depositary Shares)
that may be issued by us to the Selling Shareholder under the Purchase Agreement. Such shares of include (i) up to 35,000,000 Purchase
Shares that we may elect, in our sole discretion, to issue and sell to the Selling Shareholder, from time to time from and after the Commencement
Date under the Purchase Agreement; and (ii) up to 875,000 Commitment Shares that may be issued to the Selling Shareholder in connection
with related issuances and sales of Purchase Shares to release the Company of its liability to pay the Commitment Fee as consideration
for the Selling Shareholder’s execution and delivery of the Purchase Agreement.

As used in this prospectus,
the term “Selling Shareholder” includes the Selling Shareholder listed in the table below, and its permitted pledgees,
donees, transferees, assignees, successors, designees, successors-in-interest and others who later come to hold any of the Selling Shareholder’s
interest in the securities in accordance with the terms of the applicable agreements governing their respective registration rights, other
than through a public sale. This prospectus also covers any additional securities that may become issuable by reason of stock splits,
stock dividends or other similar transactions.

For additional information
regarding the issuance of the securities covered by this prospectus, see the section entitled “Committed Equity Financing”
above. We are registering the securities pursuant to the provisions of the Purchase Agreement and the Registration Rights Agreement in
order to permit the Selling Shareholder to offer the shares for resale from time to time. Except for the transactions contemplated by
the Purchase Agreement and the Registration Rights Agreement or as otherwise set forth in this prospectus, the Selling Shareholder has
not had any material relationship with us within the past three years.

The table below presents information
regarding the Selling Shareholder and the securities that it may offer from time to time under this prospectus. This table is prepared
based on information supplied to us by the Selling Shareholder, and reflects holdings as of January 14, 2025. The number of shares in
the column “Maximum Number of Ordinary Shares to be Offered Pursuant to this Prospectus” represents all of the Ordinary Shares
(represented by Depositary Shares) that the Selling Shareholder may offer under this prospectus. The Selling Shareholder may sell some,
all or none of its shares